Unlock stock picks and a broker-level newsfeed that powers Wall Street.

Shanghai - Delayed Quote CNY

Jointown Pharmaceutical Group Co., Ltd (600998.SS)

Compare
4.8200
-0.0200
(-0.41%)
At close: 3:00:04 PM GMT+8
Loading Chart for 600998.SS
  • Previous Close 4.8400
  • Open 4.8200
  • Bid 4.8200 x --
  • Ask 4.8300 x --
  • Day's Range 4.8000 - 4.8700
  • 52 Week Range 4.3500 - 8.6200
  • Volume 18,219,878
  • Avg. Volume 28,977,573
  • Market Cap (intraday) 24.305B
  • Beta (5Y Monthly) 0.34
  • PE Ratio (TTM) 11.76
  • EPS (TTM) 0.4100
  • Earnings Date --
  • Forward Dividend & Yield 0.25 (4.92%)
  • Ex-Dividend Date Jun 7, 2024
  • 1y Target Est --

Jointown Pharmaceutical Group Co., Ltd provides pharmaceutical supply chain services in China. It is also involved in general agency brand promotion; digital retail; intelligent logistics and supply chain solutions; and medical health and technology value-added service businesses. In addition, the company manufactures western medicines, such as antibiotics, anti-diabetic drugs, and cardiovascular drugs; and other OEM medicines. The company was founded in 1999 and is based in Wuhan, China.

www.jointown.com

30,100

Full Time Employees

December 31

Fiscal Year Ends

Recent News: 600998.SS

View More

Performance Overview: 600998.SS

Trailing total returns as of 4/11/2025, which may include dividends or other distributions. Benchmark is SSE Composite Index (000001.SS) .

YTD Return

600998.SS
5.86%
SSE Composite Index (000001.SS)
3.39%

1-Year Return

600998.SS
37.69%
SSE Composite Index (000001.SS)
6.72%

3-Year Return

600998.SS
16.50%
SSE Composite Index (000001.SS)
2.24%

5-Year Return

600998.SS
35.98%
SSE Composite Index (000001.SS)
15.79%

Compare To: 600998.SS

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Statistics: 600998.SS

View More

Valuation Measures

Annual
As of 4/10/2025
  • Market Cap

    24.41B

  • Enterprise Value

    24.32B

  • Trailing P/E

    11.91

  • Forward P/E

    --

  • PEG Ratio (5yr expected)

    --

  • Price/Sales (ttm)

    0.16

  • Price/Book (mrq)

    0.99

  • Enterprise Value/Revenue

    0.16

  • Enterprise Value/EBITDA

    5.83

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    1.37%

  • Return on Assets (ttm)

    2.67%

  • Return on Equity (ttm)

    7.15%

  • Revenue (ttm)

    149.2B

  • Net Income Avi to Common (ttm)

    2.05B

  • Diluted EPS (ttm)

    0.4100

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    16.24B

  • Total Debt/Equity (mrq)

    43.63%

  • Levered Free Cash Flow (ttm)

    1.87B

Research Analysis: 600998.SS

View More

Company Insights: 600998.SS

Research Reports: 600998.SS

View More

People Also Watch